European Society of Hypertension - ESH Education - Congress Reports, ACC.06, index

Congress Reports

American College of Cardiology
55th Annual Scientific Session
March 11-14, Atlanta

‹‹‹ Click on the dates to see the daily articles!


March 13

	Significant Reductions in Coronary Atherosclerosis with Rosuvastatin Intensive Therapy March 13, Atlanta—The majority of patients in the ASTEROID trial had regression of atherosclerotic disease associated with a treatment regimen of rosuvastatin 40 mg daily. The intensive treatment was well tolerated, with liver function changes similar to those reported in previous trials with maximal doses of statins.


March 12

	REACH registry: Disease burden remains high, despite contemporary therapy March 12, 2006, Atlanta—The 1-year findings from the REACH registry of 63,129 individuals in whom follow-up was completed showed a 3.5% event rate for cardiovascular death, myocardial infarction, stroke, even in stable patients, with or without a high risk of atherothrombosis, who were well-treated with contemporary therapies.


	CHARISMA: Two Anti-platelet drugs beneficial in secondary prevention, harmful in primary prevention The Clopidogrel for High Atherothrombotic Risk for Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial showed no significant benefit for clopidogrel plus aspirin on clinical outcomes in the median 28-months follow-up in the 15,603 patients with either documented cardiovascular disease or multiple risk factors for atherosclerosis. The patients were randomized clopidogrel 75 mg daily or placebo, all patients received low-dose aspirin.


	ARMYDA-3: Atorvastatin pre-treatment reduces post-surgical atrial fibrillation The Atorvastatin for Reduction of Myocardial Dysrhythmia After cardiac surgery (ARMYDA-3) study is the first randomized trial to indicate that pre-treatment with a statin reduces new onset post-operative atrial fibrillation (AF) in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB), independent of confounding factors.


	Simple physical movements reduce vasovagal syncope episodes: PC-Trial Physical counterpressure maneuvers reduced the number of episodes of vasovagal syncope and reduced the prodrome in a small study conducted in The Netherlands. This should be “first-line therapy in every patient presenting with vasovagal syncope,” stated Nynke van Dijk, Academic Medical Center-University of Amsterdam.


March 14

	TROPHY: Preventive treatment with candesartan beneficial in prehypertension patients March 14, 2006, Atlanta—The Trial of Preventing Hypertension (TROPHY) showed a reduction in the risk of developing hypertension in study participants who were prehypertensive treated with candesartan compared to placebo. Dr. Stevo Julius presented the results of the TROPHY study at the American College of Cardiology meeting, held in Atlanta from March 11-14, 2006, and published simultaneously online by the New England Journal of Medicine.



The materials presented here were prepared by independent authors under the editorial supervision of ESHonline, and do not represent a publication of the American Heart Association. These materials and the related activity are not sanctioned by the American Heart Association and do not constitute an official part of that conference. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © ESHonline.org.